Financial reports show that more and more listed pharmaceutical companies in China invest more than 20% of their revenue in R&D. It is this act of making a determination to carry out research and development that continues to bear fruit: China's pipeline of new drugs being developed accounts for about 30% of the world's total, ranking second in the world, and has become an important highland for new drug research and development in the world. Only by putting independent innovation first, and allowing R&D investment to continuously improve target discovery, clinical transformation, and industrialization capabilities, can domestically produced innovative drugs firmly grasp the autonomy of the industrial chain supply chain. Innovative drugs are gaining momentum, and drug regulatory reform is an important booster. Radical reforms are constantly breaking through the blockages and difficulties in the development and marketing of new drugs. The “Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry” proposes that by 2030, the first innovative drugs will account for no less than 25% of the world, and the number of innovative drugs launched will rank among the highest in the world. The goal is inspiring, time is tight, and efforts are being made to deepen independent innovation, release reform dividends, and expand open cooperation. China's innovative drugs will definitely better protect people's health, empower industrial upgrading, and shine on the global stage.

Financial reports show that more and more listed pharmaceutical companies in China invest more than 20% of their revenue in R&D. It is this act of making a determination to carry out research and development that continues to bear fruit: China's pipeline of new drugs being developed accounts for about 30% of the world's total, ranking second in the world, and has become an important highland for new drug research and development in the world. Only by putting independent innovation first, and allowing R&D investment to continuously improve target discovery, clinical transformation, and industrialization capabilities, can domestically produced innovative drugs firmly grasp the autonomy of the industrial chain supply chain. Innovative drugs are gaining momentum, and drug regulatory reform is an important booster. Radical reforms are constantly breaking through the blockages and difficulties in the development and marketing of new drugs. The “Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry” proposes that by 2030, the first innovative drugs will account for no less than 25% of the world, and the number of innovative drugs launched will rank among the highest in the world. The goal is inspiring, time is tight, and efforts are being made to deepen independent innovation, release reform dividends, and expand open cooperation. China's innovative drugs will definitely better protect people's health, empower industrial upgrading, and shine on the global stage.